这是一篇来自已证抗体库的有关人类 KRT2的综述,是根据42篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合KRT2 抗体。
KRT2 同义词: CK-2e; K2e; KRT2A; KRT2E; KRTE; keratin, type II cytoskeletal 2 epidermal; cytokeratin-2e; epithelial keratin-2e; keratin 2, type II; keratin-2 epidermis; keratin-2e; type-II keratin Kb2

赛默飞世尔
小鼠 单克隆(AE1/AE3)
  • 免疫组化-石蜡切片; 人类; 1:150; 表 2
赛默飞世尔 KRT2抗体(Zymed, AE1/AE3)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:150 (表 2). Hum Pathol (2017) ncbi
小鼠 单克隆(AE3)
  • 流式细胞仪; 人类
赛默飞世尔 KRT2抗体(eBioscience, 14-900-80)被用于被用于流式细胞仪在人类样本上. F1000Res (2016) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化; 人类; 图 3d
赛默飞世尔 KRT2抗体(Thermo Scientific, AE1-AE3)被用于被用于免疫组化在人类样本上 (图 3d). Case Rep Pathol (2016) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化-石蜡切片; 人类; 图 5b
赛默飞世尔 KRT2抗体(Thermo Scientific, AE1/AE3)被用于被用于免疫组化-石蜡切片在人类样本上 (图 5b). Breast Cancer Res Treat (2016) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫细胞化学; 人类; 1:50; 图 1
赛默飞世尔 KRT2抗体(ThermoFisher Scientific, MA5-13156)被用于被用于免疫细胞化学在人类样本上浓度为1:50 (图 1). Future Oncol (2016) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化-石蜡切片; 人类; 图 s3
赛默飞世尔 KRT2抗体(分子探针, 985542A)被用于被用于免疫组化-石蜡切片在人类样本上 (图 s3). Microbiome (2015) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化; 人类; 图 s3
赛默飞世尔 KRT2抗体(Neomarkers, MS-343-P)被用于被用于免疫组化在人类样本上 (图 s3). Mol Cancer (2015) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化-石蜡切片; 人类; 1:50; 图 3
赛默飞世尔 KRT2抗体(Zymed, AE1/AE3)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:50 (图 3). Pathol Res Pract (2015) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫细胞化学; 小鼠; 1:100; 表 2
赛默飞世尔 KRT2抗体(eBioscience, 41-9003)被用于被用于免疫细胞化学在小鼠样本上浓度为1:100 (表 2). J Cell Physiol (2016) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化; 人类; 表 2
赛默飞世尔 KRT2抗体(Thermo Scientific, AE1/AE3)被用于被用于免疫组化在人类样本上 (表 2). Diagn Cytopathol (2015) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫细胞化学; fancy carp
赛默飞世尔 KRT2抗体(生活技术, MA5-13156)被用于被用于免疫细胞化学在fancy carp样本上. In Vitro Cell Dev Biol Anim (2015) ncbi
小鼠 单克隆(AE1/AE3)
  • 流式细胞仪; 人类
  • 免疫细胞化学; 人类; 1 ul
赛默飞世尔 KRT2抗体(eBioscience, 53-9003-82)被用于被用于流式细胞仪在人类样本上 和 被用于免疫细胞化学在人类样本上浓度为1 ul. Nanomedicine (2015) ncbi
小鼠 单克隆(AE1/AE3)
赛默飞世尔 KRT2抗体(Invitrogen, AE1/AE3)被用于. In Vitro Cell Dev Biol Anim (2015) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫细胞化学; equine; 1:100
赛默飞世尔 KRT2抗体(Fisher Scientific, MA1-82041)被用于被用于免疫细胞化学在equine样本上浓度为1:100. Equine Vet J (2016) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化-石蜡切片; 人类; 10-20 ug/ml
赛默飞世尔 KRT2抗体(Lab.Vision, Ab-1)被用于被用于免疫组化-石蜡切片在人类样本上浓度为10-20 ug/ml. Asian Pac J Cancer Prev (2015) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化-石蜡切片; 小鼠; 1:100; 图 s6
赛默飞世尔 KRT2抗体(Thermo, MS-34)被用于被用于免疫组化-石蜡切片在小鼠样本上浓度为1:100 (图 s6). Nat Commun (2015) ncbi
小鼠 单克隆(AE3)
  • 免疫组化-石蜡切片; 小鼠; 1:100; 图 s6
赛默飞世尔 KRT2抗体(Thermo, MS-34)被用于被用于免疫组化-石蜡切片在小鼠样本上浓度为1:100 (图 s6). Nat Commun (2015) ncbi
小鼠 单克隆(AE1/AE3)
  • 流式细胞仪; 斑马鱼; 1:100; 图 5
赛默飞世尔 KRT2抗体(Thermo Fisher Scientific, MA1-82041)被用于被用于流式细胞仪在斑马鱼样本上浓度为1:100 (图 5). Nat Commun (2014) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化-石蜡切片; 小鼠; 1:200; 图 5
赛默飞世尔 KRT2抗体(ThermoFisher Scientific, AE1/AE3)被用于被用于免疫组化-石蜡切片在小鼠样本上浓度为1:200 (图 5). Development (2015) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化-石蜡切片; 人类; 1:100
赛默飞世尔 KRT2抗体(Neo Markers, MS343)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100. Comp Med (2014) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化-石蜡切片; 人类; 1:200; 图 3
赛默飞世尔 KRT2抗体(eBioscience, 53-9003-80)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:200 (图 3). Nat Cell Biol (2014) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化-石蜡切片; 人类; 1:100
赛默飞世尔 KRT2抗体(Zymed, AE1/AE3)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100. Hum Pathol (2014) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化-石蜡切片; 人类; 1:100
赛默飞世尔 KRT2抗体(Thermo Fisher Scientific, AE1/AE3)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100. Rom J Morphol Embryol (2014) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫细胞化学; 人类
赛默飞世尔 KRT2抗体(Invitrogen, AE1/AE3)被用于被用于免疫细胞化学在人类样本上. Histopathology (2015) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化; 人类
赛默飞世尔 KRT2抗体(Thermo, AE1/AE3)被用于被用于免疫组化在人类样本上. BMC Med Imaging (2013) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫细胞化学; 人类
赛默飞世尔 KRT2抗体(Thermo Fisher, AE1/AE3)被用于被用于免疫细胞化学在人类样本上. Biomed Mater (2013) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 KRT2抗体(Thermoelectron, AE1/AE3)被用于被用于免疫组化-石蜡切片在人类样本上. BMC Med Imaging (2013) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化-石蜡切片; 人类; 1:100; 表 2
赛默飞世尔 KRT2抗体(Invitrogen, AE1/AE3)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100 (表 2). Sci Rep (2013) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫细胞化学; 人类; 1:100; 图 1
赛默飞世尔 KRT2抗体(eBioscience, AE1/AE3)被用于被用于免疫细胞化学在人类样本上浓度为1:100 (图 1). PLoS ONE (2013) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化; 人类; 表 1
赛默飞世尔 KRT2抗体(Invitrogen, AE1/AE3)被用于被用于免疫组化在人类样本上 (表 1). Head Face Med (2013) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化; 人类; 1:200; 图 4
赛默飞世尔 KRT2抗体(Zymed, AE1-AE3)被用于被用于免疫组化在人类样本上浓度为1:200 (图 4). Surg Neurol Int (2013) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化; 人类; 图 2
赛默飞世尔 KRT2抗体(Invitrogen, AE1/AE3)被用于被用于免疫组化在人类样本上 (图 2). Diagn Pathol (2013) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫细胞化学; 大西洋鲑鱼; 1:50; 图 2
赛默飞世尔 KRT2抗体(Invitrogen, AE1/AE3)被用于被用于免疫细胞化学在大西洋鲑鱼样本上浓度为1:50 (图 2). Virol J (2013) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化-石蜡切片; 人类; 1:100
赛默飞世尔 KRT2抗体(Invitrogen, AE1/AE3)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100. Med Sci Monit (2012) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化-石蜡切片; 小鼠
赛默飞世尔 KRT2抗体(Thermo Scientific, MS-343)被用于被用于免疫组化-石蜡切片在小鼠样本上. Anat Cell Biol (2011) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化-石蜡切片; 人类; 1:200
赛默飞世尔 KRT2抗体(Neomarkers, MS 343-P)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:200. PLoS ONE (2011) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化; 人类; 0.4 ug/ul; 图 1
赛默飞世尔 KRT2抗体(NeoMarkers, MS-343)被用于被用于免疫组化在人类样本上浓度为0.4 ug/ul (图 1). Eur J Oral Sci (2010) ncbi
小鼠 单克隆(AE3)
  • 免疫组化-石蜡切片; 人类; 1:300; 表 2
赛默飞世尔 KRT2抗体(Zymed, AE3)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:300 (表 2). J Comp Pathol (2009) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化-石蜡切片; 人类; 1:200
赛默飞世尔 KRT2抗体(Zymed, AE1/AE3)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:200. Cancer (2008) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫印迹; 人类; 图 5
赛默飞世尔 KRT2抗体(Lab Vision, MS-343-P)被用于被用于免疫印迹在人类样本上 (图 5). Int J Cancer (2005) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫组化-石蜡切片; 人类; 1:80; 表 1
赛默飞世尔 KRT2抗体(Zymed, AE1/AE3)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:80 (表 1). Pathol Int (2004) ncbi
小鼠 单克隆(AE1/AE3)
  • 免疫印迹; 人类; 1:1000; 图 2
赛默飞世尔 KRT2抗体(Zymed, AE1/AE3)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 2). Gynecol Oncol (2003) ncbi
Progen
小鼠 单克隆(AE3)
  • 免疫组化-石蜡切片; 牛; 1:100; 图 st6
  • 免疫组化-石蜡切片; 狗; 1:100; 图 st6
Progen KRT2抗体(Progen, 61806)被用于被用于免疫组化-石蜡切片在牛样本上浓度为1:100 (图 st6) 和 被用于免疫组化-石蜡切片在狗样本上浓度为1:100 (图 st6). J Toxicol Pathol (2017) ncbi
文章列表
  1. Wang X, Xia Q, Ni H, Ye S, Li R, Wang X, et al. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion. Hum Pathol. 2017;63:190-200 pubmed 出版商
  2. Furukawa S, Nagaike M, Ozaki K. Databases for technical aspects of immunohistochemistry. J Toxicol Pathol. 2017;30:79-107 pubmed 出版商
  3. Kwon Y, Stanciu C, Philpott M, Ehrhardt C. Flow cytometry dataset for cells collected from touched surfaces. F1000Res. 2016;5:390 pubmed 出版商
  4. De Luca Johnson J, Zenali M. A Previously Undescribed Presentation of Mixed Adenoneuroendocrine Carcinoma. Case Rep Pathol. 2016;2016:9063634 pubmed
  5. Szalayova G, Ogrodnik A, Spencer B, Wade J, Bunn J, Ambaye A, et al. Human breast cancer biopsies induce eosinophil recruitment and enhance adjacent cancer cell proliferation. Breast Cancer Res Treat. 2016;157:461-74 pubmed 出版商
  6. Fabbri R, Macciocca M, Vicenti R, Paradisi R, Klinger F, Pasquinelli G, et al. Doxorubicin and cisplatin induce apoptosis in ovarian stromal cells obtained from cryopreserved human ovarian tissue. Future Oncol. 2016;12:1699-711 pubmed 出版商
  7. Shin H, Pei Z, Martinez K, Rivera Viñas J, Méndez K, Cavallin H, et al. The first microbial environment of infants born by C-section: the operating room microbes. Microbiome. 2015;3:59 pubmed 出版商
  8. van Jaarsveld M, van Kuijk P, Boersma A, Helleman J, Van Ijcken W, Mathijssen R, et al. miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway. Mol Cancer. 2015;14:196 pubmed 出版商
  9. Jung M, Ryu Y, Kang G. Investigation of the origin of stromal and endothelial cells at the desmoplastic interface in xenograft tumor in mice. Pathol Res Pract. 2015;211:925-30 pubmed 出版商
  10. Li Y, Adomat H, Guns E, Hojabrpour P, Duronio V, Curran T, et al. Identification of a Hematopoietic Cell Dedifferentiation-Inducing Factor. J Cell Physiol. 2016;231:1350-63 pubmed 出版商
  11. Sauter J, Ambaye A, Mount S. Increased utilization, verification, and clinical implications of immunocytochemistry: Experience in a northern New England hospital. Diagn Cytopathol. 2015;43:688-95 pubmed 出版商
  12. Swaminathan T, Basheer V, Kumar R, Kathirvelpandian A, Sood N, Jena J. Establishment and characterization of fin-derived cell line from ornamental carp, Cyprinus carpio koi, for virus isolation in India. In Vitro Cell Dev Biol Anim. 2015;51:705-13 pubmed 出版商
  13. Muhanna N, Mepham A, Mohamadi R, Chan H, Khan T, Akens M, et al. Nanoparticle-based sorting of circulating tumor cells by epithelial antigen expression during disease progression in an animal model. Nanomedicine. 2015;11:1613-20 pubmed 出版商
  14. Sood N, Chaudhary D, Pradhan P, Verma D, Raja Swaminathan T, Kushwaha B, et al. Establishment and characterization of a continuous cell line from thymus of striped snakehead, Channa striatus (Bloch 1793). In Vitro Cell Dev Biol Anim. 2015;51:787-96 pubmed 出版商
  15. Aguiar C, Therrien J, Lemire P, Segura M, Smith L, Theoret C. Differentiation of equine induced pluripotent stem cells into a keratinocyte lineage. Equine Vet J. 2016;48:338-45 pubmed 出版商
  16. Ahmed H, Abdul Gader Suliman R, Abd El Aziz M, Alshammari F. Immunohistochemical expression of cytokeratins and epithelial membrane protein 2 in nasopharyngeal carcinoma and its potential implications. Asian Pac J Cancer Prev. 2015;16:653-6 pubmed
  17. Zheng L, Cardaci S, Jerby L, MacKenzie E, Sciacovelli M, Johnson T, et al. Fumarate induces redox-dependent senescence by modifying glutathione metabolism. Nat Commun. 2015;6:6001 pubmed 出版商
  18. Progatzky F, Sangha N, Yoshida N, McBrien M, Cheung J, Shia A, et al. Dietary cholesterol directly induces acute inflammasome-dependent intestinal inflammation. Nat Commun. 2014;5:5864 pubmed 出版商
  19. Suzuki D, Sahu R, Leu N, Senoo M. The carboxy-terminus of p63 links cell cycle control and the proliferative potential of epidermal progenitor cells. Development. 2015;142:282-90 pubmed 出版商
  20. Beck A, Brooks A, Zeiss C. Invasive ductular carcinoma in 2 rhesus macaques (Macaca mulatta). Comp Med. 2014;64:314-22 pubmed
  21. Lu H, Clauser K, Tam W, Fröse J, Ye X, Eaton E, et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol. 2014;16:1105-17 pubmed 出版商
  22. Li L, Fan X, Xia Q, Rao Q, Liu B, Yu B, et al. Concurrent loss of INI1, PBRM1, and BRM expression in epithelioid sarcoma: implications for the cocontributions of multiple SWI/SNF complex members to pathogenesis. Hum Pathol. 2014;45:2247-54 pubmed 出版商
  23. Costache M, Pătraşcu O, Dumitru A, Costache D, Voinea L, Simionescu O, et al. Histopathological findings concerning ocular melanomas. Rom J Morphol Embryol. 2014;55:649-53 pubmed
  24. Guan H, Tan J, Zhang F, Gao L, Bai L, Qi D, et al. Myofibroblasts from salivary gland adenoid cystic carcinomas promote cancer invasion by expressing MMP2 and CXCL12. Histopathology. 2015;66:781-90 pubmed 出版商
  25. Motomura K, Sumino H, Noguchi A, Horinouchi T, Nakanishi K. Sentinel nodes identified by computed tomography-lymphography accurately stage the axilla in patients with breast cancer. BMC Med Imaging. 2013;13:42 pubmed 出版商
  26. Bulysheva A, Bowlin G, Petrova S, Yeudall W. Enhanced chemoresistance of squamous carcinoma cells grown in 3D cryogenic electrospun scaffolds. Biomed Mater. 2013;8:055009 pubmed 出版商
  27. Motomura K, Izumi T, Tateishi S, Sumino H, Noguchi A, Horinouchi T, et al. Correlation between the area of high-signal intensity on SPIO-enhanced MR imaging and the pathologic size of sentinel node metastases in breast cancer patients with positive sentinel nodes. BMC Med Imaging. 2013;13:32 pubmed 出版商
  28. Qiu S, Wei X, Huang W, Wu M, Qin Y, Li Y, et al. Diagnostic and therapeutic strategy and the most efficient prognostic factors of breast malignant fibrous histiocytoma. Sci Rep. 2013;3:2529 pubmed 出版商
  29. Hosokawa M, Kenmotsu H, Koh Y, Yoshino T, Yoshikawa T, Naito T, et al. Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system. PLoS ONE. 2013;8:e67466 pubmed 出版商
  30. Ohta K, Taki M, Ogawa I, Ono S, Mizuta K, Fujimoto S, et al. Malignant ossifying fibromyxoid tumor of the tongue: case report and review of the literature. Head Face Med. 2013;9:16 pubmed 出版商
  31. Nassiri F, Scheithauer B, Corwin D, Kaplan H, Mayberg M, Cusimano M, et al. Invasive thymoma metastatic to the cavernous sinus. Surg Neurol Int. 2013;4:74 pubmed 出版商
  32. Yang G, Li J, Jin H, Ding H. Is mammary not otherwise specified-type sarcoma with CD10 expression a distinct entity? A rare case report with immunohistochemical and ultrastructural study. Diagn Pathol. 2013;8:14 pubmed 出版商
  33. Weli S, Aamelfot M, Dale O, Koppang E, Falk K. Infectious salmon anaemia virus infection of Atlantic salmon gill epithelial cells. Virol J. 2013;10:5 pubmed 出版商
  34. Lv S, Song Y, Xu J, Shu H, Zhou Z, An N, et al. A novel TP53 somatic mutation involved in the pathogenesis of pediatric choroid plexus carcinoma. Med Sci Monit. 2012;18:CS37-41 pubmed
  35. Sohn W, Gwon G, An C, Moon C, Bae Y, Yamamoto H, et al. Morphological evidences in circumvallate papilla and von Ebners' gland development in mice. Anat Cell Biol. 2011;44:274-83 pubmed 出版商
  36. Kap M, Smedts F, Oosterhuis W, Winther R, Christensen N, Reischauer B, et al. Histological assessment of PAXgene tissue fixation and stabilization reagents. PLoS ONE. 2011;6:e27704 pubmed 出版商
  37. Brusevold I, Husvik C, Schreurs O, Schenck K, Bryne M, Søland T. Induction of invasion in an organotypic oral cancer model by CoCl2, a hypoxia mimetic. Eur J Oral Sci. 2010;118:168-76 pubmed 出版商
  38. Gil da Costa R, Santos M, Amorim I, Lopes C, Pereira P, Faustino A. An immunohistochemical study of feline endometrial adenocarcinoma. J Comp Pathol. 2009;140:254-9 pubmed 出版商
  39. Rodriguez F, Scheithauer B, Giannini C, Bryant S, Jenkins R. Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study. Cancer. 2008;113:2779-89 pubmed 出版商
  40. Lu S, Yu G, Zhu Y, Archer M. Cyclooxygenase-2 overexpression in MCF-10F human breast epithelial cells inhibits proliferation, apoptosis and differentiation, and causes partial transformation. Int J Cancer. 2005;116:847-52 pubmed
  41. Song S, Park S, Kim S, Suh Y. Oncocytic adrenocortical carcinomas: a pathological and immunohistochemical study of four cases in comparison with conventional adrenocortical carcinomas. Pathol Int. 2004;54:603-10 pubmed
  42. Kokenyesi R, Murray K, Benshushan A, Huntley E, Kao M. Invasion of interstitial matrix by a novel cell line from primary peritoneal carcinosarcoma, and by established ovarian carcinoma cell lines: role of cell-matrix adhesion molecules, proteinases, and E-cadherin expression. Gynecol Oncol. 2003;89:60-72 pubmed